51˶

Entresto: Why Is There Silence? We're Not Selling iPhones

— The drug hailed as a true PARADIGM shift, is slow out of the gate

by Editor-in-Chief, 51˶

MedpageToday

This article is a collaboration between 51˶ and:

CHICAGO -- More than 18 months after , reported that Entresto (sacubitril/valsarta) reduced mortality in heart failure, and 8 months after the FDA approved the drug, guidelines have not been changed and physicians have been slow to prescribe it. Why?